US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a total consideration of USD 1.135 billion. This transaction includes a USD 35 million investment made in 2022, a USD 200 million upfront payment in 2023, and additional regulatory milestone payments totaling USD 125 million, along with commercial milestone payment commitments of USD 775 million extending to 2029.
Strengthening Vascular Solutions with SELUTION SLR
MedAlliance is renowned for its innovative sirolimus drug elution balloon (DEB), the SELUTION SLR, which received CE mark approval for the treatment of peripheral arterial diseases in February 2020. Additionally, the product gained marketing approval for coronary artery diseases in May 2020. In the United States, SELUTION SLR has been cleared for use in treating below the knee (BTK) lesions, superficial femoral artery (SFA) conditions, coronary artery stent restenosis (ISR), and new onset coronary artery lesions.
Strategic Move to Expand Market Reach
This acquisition positions Cardinal Health to enhance its vascular intervention offerings significantly, leveraging MedAlliance’s advanced technologies and expanding its market reach in critical areas of cardiovascular care. The integration of SELUTION SLR into Cardinal Health’s portfolio is expected to drive growth and innovation in the vascular intervention space.-Fineline Info & Tech
